Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trident-1 in acute decompensated heart failure with renal insufficiency
ACTRN12608000607370Phase 3Terminated
- Sponsor
- Biogen
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of Adentri in heart failure (HF) (4 arms), sponsored by Biogen. Primary endpoint: Change in body weight. Started Sep 2008; status: terminated.
02
Drugs
Adentri
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ACTRN12608000607370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000607370.